Maximizing survival benefit with precision therapy based on progressive patterns after immunochemotherapy in metastatic esophageal cancer.

ABSTRACT: This study aimed to define optimal treatment strategies for metastatic esophageal cancer with different progressive patterns after first-line immunotherapy (IO) resistance. Patients were stratified into oligoprogression and polyprogression, with further subclassifications (repeat oligoprogression [REO]/induced oligoprogression [INO]/de-novo polyprogression [DNP]/repeat polyprogression [REP]). Oligoprogression patients receiving radiotherapy (RT) had longer progression-free survival (PFS) (9.4 vs. 5.8 months, p = 0.018, q = 0.036) and overall survival (OS) (21.9 vs. 9.2 months, p = 0.012, q = 0.024), especially in the REO subgroup (PFS: 9.4 vs. 5.7 months, p = 0.0249, q = 0.0498; OS: 21.9 vs. 8.7 months, p = 0.018, q = 0.036). Polyprog

SUBMITTER: Liu Y 

PROVIDER: S-EPMC12767177 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature